Pharmacokinetics of iodine-131-labeled chimeric monoclonal antibody in lung cancer patients

Journal of China Pharmaceutical University

Volumn 35, Issue 2, 2004, Pages 164-167

  Chen, Yang Chun ^a   Chen, Shao Liang ^a   Ju, Dian Wen ^b   Shi, Hong Cheng ^a   Xu, Kai Ping ^a   Xu, Chang De ^a  

^a FUDAN UNIVERSITY   (China)

^b Shanghai Medipharm Biotech Co Ltd   (China)

Author keywords

Chimeric monoclonal antibody (chTNT); Pharmacokinetics; Radioimmunotherapy

Indexed keywords

CANCER ANTIBODY; CHIMERIC ANTIBODY; DRUG METABOLITE; IODINE; MONOCLONAL ANTIBODY I 131;

ARTICLE; BLOOD POOL SCINTISCANNING; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG STABILITY; FOLLOW UP; GEOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMAGING SYSTEM; ISOTOPE LABELING; LIVER; LUNG; LUNG CANCER; LUNG TUMOR; MATHEMATICAL MODEL; RADIOACTIVITY; RADIOIMMUNOTHERAPY; SCINTILLATION CAMERA; SINGLE DRUG DOSE; THYROID FUNCTION; TISSUE DISTRIBUTION; URINALYSIS;

EID: 2942577629     PISSN: 10005048     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Hornick JL, Sharifi J, Khawli LA, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors[J]. Cancer Biother Radiopharm, 1998,13(4):255-268.
2. Hornick JL, Sharifi J, Khawli LA, et al. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraghy of solid tumors [J]. J Nucl Med, 2000,41(2):355-362.
3. Chinese source. 2001.4.
4. Eary JF, Appelbaum FI, Durack L, et al. Preliminary validation of the opposing view mothod for quantitative gamma camera imaging [J]. Med Phys, 1989,16(3):382-387.
5. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from Technetium-99m-labeled antibodies and results of phase I trials[J]. J Nucl Med, 1993,34:908-917.
6. Nachar O, Rousseau JA, Leflbvre B, et al. Biodistribution, dosimetry and metabolism of 11β-methoxy-(17α, 20E/Z)-[ 1231 ] iodovinylestradiol in healthy women and breast cancer patients[J]. J Nucl Med, 1999,40:1728-1736.